^
Association details:
| Biomarker: | RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | soxataltinib (SY-5007) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multicenter, open-label phase III study evaluating the efficacy and safety of the RET inhibitor SY-5007 tablets in patients with RET fusion-positive advanced non-small cell lung cancer.
Excerpt:
......
Source:
Title:
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Excerpt:
...Previous tumor tissue or blood samples are confirmed as RET fusion positive by local laboratory testing....
Trial ID:
More C2 evidence
Source:
Title:
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
Excerpt:
...Patients with advanced tumor must have histological or cytological confirmed RET alteration, including NSCLC patients with RET-fusion or MTC patients with RET-mutation or other patients with RET alteration, and either have progressed after standard therapy or...
Trial ID:
Less C2 evidence
Source:
Title:
A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.
Published date:
05/25/2023
Excerpt:
SY-5007 was well tolerated in patients. Preliminary antitumor activity was also observed in patients with advanced RET-fusion positive NSCLC and RET mutant MTC.
DOI:
10.1200/JCO.2023.41.16_suppl.9111
Trial ID: